Eli Lilly has been experiencing strong growth lately due to its impressive GLP-1 drugs. Eli Lilly (NYSE: LLY) has been a ...

Tiger Global's tech-focused portfolio hits $26.59B with Meta, Microsoft, and Amazon leading. Discover new positions and ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

On Tuesday, Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE: LLY) entered into a collaboration and license agreement.

Eli Lilly (NYSE: LLY) has been one of the top-performing healthcare megacap stocks of the past decade. Eli Lilly is ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help extend the durability of up to four of its weight-loss medicines.

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

No drug is without potential side effects, and there are five major ones that people taking Ozempic, Wegovy or Mounjaro are ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad ...

With a market cap of around $136 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company. The Foster City, ...